SCHEMBL134968

SCHEMBL134968

CCC(=O)N(CC)CCO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
ALDH2 P05091 2/20 0.46
LMNA P02545 1/20 0.42
KDM4E B2RXH2 3/20 0.36
HPGD P15428 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
HSD17B10 Q99714 2/20 0.36
GAA P10253 1/20 0.36
MMP1 P03956 1/20 0.36
MMP2 P08253 1/20 0.36
MMP3 P08254 1/20 0.36
MMP8 P22894 1/20 0.36
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA9 Q16790 2/20 0.35
POLB P06746 2/20 0.35
ALOX15 P16050 1/20 0.35
MAPT P10636 1/20 0.33
CA2 P00918 1/20 0.33
TSPO P30536 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3628031 0.90 POLB (0.41) ALDH1A1ALDH2LMNAKDM4EHPGD
SCHEMBL8633814 0.86 LMNA (0.44) ALDH1A1ALDH2LMNAHPGDGAA
SCHEMBL28912905 0.85 ALDH1A1 (0.46) ALDH1A1ALDH2LMNAKDM4EHPGD
SCHEMBL1396575 0.85 ALDH1A1 (0.37) ALDH1A1ALDH2LMNAKDM4EHPGD
SCHEMBL13246032 0.84 LMNA (0.43) ALDH1A1ALDH2LMNAKDM4EHSD17B10
SCHEMBL8634142 0.83 ALDH1A1 (0.48) ALDH1A1ALDH2KDM4EHPGDL3MBTL1
SCHEMBL5465384 0.83 LMNA (0.52) ALDH1A1ALDH2LMNAKDM4EHPGD
SCHEMBL10489425 0.82 CA12 (0.48) ALDH1A1ALDH2LMNAHPGDMMP1
SCHEMBL25163064 0.81 LMNA (0.62) ALDH1A1ALDH2LMNAHPGDL3MBTL1
SCHEMBL22271561 0.81 ALDH1A1 (0.43) ALDH1A1ALDH2LMNAKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5851274-A Ink jet ink compositions and processes for high resolution and high speed printing XEROX CORPORATION (US) 1998-12-22 US claimed
EP-0853107-A1 Ink jet ink compositions comprising hydroxyamide derivatives and printing processes XEROX CORPORATION (US) 1998-07-15 EP claimed
EP-0853108-A1 Ink jet ink compositions and processes for high resolution and high speed printing XEROX CORPORATION (US) 1998-07-15 EP claimed
US-5693129-A AQUEOUS MIXCTURE CONTAINING COLORING AND A HYDROXYAMIDE, THIOAMIDE, MERCAPTOAMIDE, MERCAPTOTHIOAMIDE OR AN OXYALKYLENE OR A THIOALKYLENE REACTION PRODUCT OF THE AMIDES, FOR HIGH RESOLUTION, REDUCED CURLING XEROX CORPORATION (US) 1997-12-02 US claimed
CN-119841829-A Compounds for the treatment of PI3K gamma mediated diseases and uses thereof 中国科学院合肥物质科学研究院 2025-04-18 CN disclosed
US-8288540-B2 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors IRM LLC (BM) 2012-10-16 US disclosed
EP-2425831-A1 SCCA-1 PRODUCTION INHIBITOR HAVING A CARBOXAMIDE DERIVATIVE AND/OR A SALT THEREOF AS AN ACTIVE INGREDIENT Shiseido Co., Ltd. (JP) 2012-03-07 EP disclosed
US-8002120-B2 Modified polyamide membrane DOW GLOBAL TECHNOLOGIES LLC (US) 2011-08-23 US disclosed
US-20110120942-A1 MODIFIED POLYAMIDE MEMBRANE THE DOW CHEMICAL COMPANY 2011-05-26 US disclosed
US-7905361-B2 Polyamides modified with oxazoline, thiazoline compounds; overcoating with polyoxazoline or polyoxyethylene glycol; heating; reduced fouling, microbiocides, storage stability DOW GLOBAL TECHNOLOGIES LLC (US) 2011-03-15 US disclosed
US-20110053952-A1 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-7897601-B2 Cannabinoid receptor modulators INTERVET, INC. (US) 2011-03-01 US disclosed
US-20080139559-A1 DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) 2008-06-12 US disclosed
US-20070197628-A1 Cannabinoid receptor modulators INTERVET INTERNATIONAL B.V. (NL) 2007-08-23 US disclosed
US-20070149538-A1 Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors IRM LLC (BM) 2007-06-28 US disclosed
US-5851274-A Ink jet ink compositions and processes for high resolution and high speed printing XEROX CORPORATION (US) 1998-12-22 US disclosed
EP-0853107-A1 Ink jet ink compositions comprising hydroxyamide derivatives and printing processes XEROX CORPORATION (US) 1998-07-15 EP disclosed
EP-0853108-A1 Ink jet ink compositions and processes for high resolution and high speed printing XEROX CORPORATION (US) 1998-07-15 EP disclosed
US-5693129-A AQUEOUS MIXCTURE CONTAINING COLORING AND A HYDROXYAMIDE, THIOAMIDE, MERCAPTOAMIDE, MERCAPTOTHIOAMIDE OR AN OXYALKYLENE OR A THIOALKYLENE REACTION PRODUCT OF THE AMIDES, FOR HIGH RESOLUTION, REDUCED CURLING XEROX CORPORATION (US) 1997-12-02 US disclosed
US-4035190-A 2-ISOXAZOLIN-3-HETEROCYCLIC-SUBSTITUTED MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1977-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197628-A1 Cannabinoid receptor modulators CNR1, CNR2, GPR18 ALDH1A1 1999/4885ALDH2 2218/4885LMNA 3635/4885
US-20110053952-A1 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS FYN, LCK, ERBB2 ALDH1A1 3888/4885ALDH2 3842/4885LMNA 4877/4885
US-20070149538-A1 Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors KIT, PRKCH, PRKCE ALDH1A1 1472/4885ALDH2 2076/4885LMNA 710/4885
US-20080139559-A1 DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS KIT, PRKCH, PRKCE ALDH1A1 1472/4885ALDH2 2076/4885LMNA 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.